Preclinical News and Research

RSS

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Teva Pharmaceutical Industries Ltd. announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.

10 Nov 2009

Environmental factors, obesity and diabetes: Long-term study launched

Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.

10 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

Commonwealth Biotechnologies divest assets of its bioanalytical and genetic testing business units

Commonwealth Biotechnologies, Inc. is pleased to announce that it has completed the divestment of the assets (excluding land and buildings) of its bioanalytical and genetic testing business units, CBI Services and Fairfax Identity Laboratory (FIL) for a cash consideration and an ongoing lease commitment for 5 years.

10 Nov 2009

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences, Inc. today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines.

9 Nov 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline.

9 Nov 2009

AMRI reports $47.7 million total revenue for the third quarter of 2009

AMRI today reported financial and operating results for the third quarter ended September 30, 2009.

9 Nov 2009

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China.

9 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

Third-quarter 2009 financial results announced by Inhibitex

Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

6 Nov 2009

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. By a growing consensus, defining the "silent" phase of AD has become the field's central challenge if it is to modernize drug testing and lay the groundwork for AD prevention trials.

6 Nov 2009

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.

5 Nov 2009

Preclinical News and Research

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Environmental factors, obesity and diabetes: Long-term study launched

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

Commonwealth Biotechnologies divest assets of its bioanalytical and genetic testing business units

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

EpiCept announces third quarter 2009 financial results

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

AMRI reports $47.7 million total revenue for the third quarter of 2009

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

Locus Pharmaceuticals creates a new division, Ansaris

GeoVax Labs announces financial results and operational update for the third quarter of 2009

Third-quarter 2009 financial results announced by Inhibitex

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics